Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | CLK2 | P49760 | 2/20 | 0.52 |
| ▸ | CLK3 | P49761 | 2/20 | 0.52 |
| ▸ | WNT1 | P04628 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16712951 | 0.93 | RAB9A (0.62) | RAB9ANPC1TP53ALOX15SMN1; SMN2 | |
| SCHEMBL16702122 | 0.91 | SCN1A (0.57) | RAB9ANPC1MAPK14LCKKDR | |
| SCHEMBL16701407 | 0.91 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL16701405 | 0.90 | RAB9A (0.62) | RAB9ANPC1KMT2AMAPK14LCK | |
| SCHEMBL16701477 | 0.90 | LCK (0.52) | RAB9ANPC1KMT2AMAPTMAPK14 | |
| SCHEMBL23969958 | 0.90 | DYRK1A (0.52) | RAB9ANPC1KMT2AMAPK14LCK | |
| SCHEMBL16701626 | 0.90 | LCK (0.52) | RAB9ANPC1KMT2AMAPK14LCK | |
| SCHEMBL16701461 | 0.89 | NPC1 (0.55) | RAB9ANPC1SMN1; SMN2MAPK14LCK | |
| SCHEMBL16701543 | 0.89 | ADORA3 (0.65) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL16701479 | 0.89 | MAPK14 (0.55) | RAB9ANPC1TP53SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066072-B1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIV KANSAS (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3066072-B1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIV KANSAS (US) | 2021-11-03 | — | — | EP | disclosed |
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3066072-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | The University of Kansas (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
| US-8692018-B2 | Application of iridium complexes in asymmetric catalytic hydrogenation of unsaturated carboxylic acids | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2014-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | RAB9A 2464/4885NPC1 1414/4885TP53 76/4885 |
| US-20160272584-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | RAB9A 2464/4885NPC1 1414/4885TP53 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.